Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2016, Article ID 2867916, 9 pages
Research Article

Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010

1Department of Nuclear Medicine, Western University, London, ON, Canada
2Department of Radiation Oncology, Dalhousie University, Halifax, NS, Canada
3Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada
4Department of Endocrinology, Women’s College Hospital, Toronto, ON, Canada
5Department of Radiology and Nuclear Medicine, Memorial University, St. John’s, NL, Canada
6Department of Medicine, Dalhousie University, Halifax, NS, Canada
7Department of Surgery, McMaster University, Hamilton, ON, Canada
8Department of Surgery, University of Manitoba, Winnipeg, MB, Canada
9Department of Medicine, Western University, London, ON, Canada

Received 28 July 2016; Accepted 20 October 2016

Academic Editor: Julie A. Sosa

Copyright © 2016 I. Rachinsky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Use of radioactive iodine (RAI) ablation has been reported to vary significantly between studies. We explored variation in RAI ablation care patterns between seven thyroid cancer treatment centers in Canada. Methods. The Canadian Collaborative Network for Cancer of the Thyroid (CANNECT) is a collaborative registry to describe and analyze patterns of care for thyroid cancer. We analyzed data from seven participating centers on RAI ablation in patients diagnosed with well-differentiated (papillary and follicular) thyroid cancer between 2000 and 2010. We compared RAI ablation protocols including indications (based on TNM staging), preparation protocols, and administered dose. We excluded patients with known distant metastases at time of RAI ablation. Results. We included 3072 patients. There were no significant differences in TNM stage over time. RAI use increased in earlier years and then declined. The fraction of patients receiving RAI varied significantly between centers, ranging between 20–85% for T1, 44–100% for T2, 58–100% for T3, and 59–100% for T4. There were significant differences in the RAI doses between centers. Finally, there was major variation in the use of thyroid hormone withdrawal or rhTSH for preparation of RAI ablation. Conclusion. Our study identified significant variation in use of RAI for ablation in patients with well-differentiated thyroid cancer both between Canadian centers and over time.